Receptor Pharmacogenomics: Deciphering Genetic Influence on Drug Response

Area of Science:

• Pharmacogenomics
• Precision Medicine
• Molecular Pharmacology

Background:

• Current
• one drug fits all
• clinical practice often overlooks interindividual genetic variability, leading to diverse drug responses.
• Pharmacogenetic research highlights the need for personalized therapeutic strategies.
• Plasma membrane proteins, including receptor tyrosine kinases (RTKs) and G protein-coupled receptors (GPCRs), are crucial drug targets.
• Over 30% of FDA-approved drugs target GPCRs, underscoring the importance of their genetic variability.

Purpose of the Study:

• To emphasize the growing role of pharmacogenomics in challenging traditional dosing paradigms.
• To highlight the significance of genetic variations in transmembrane protein receptors for personalized medicine.
• To advocate for the integration of pharmacogenomic data into clinical practice for optimized drug therapy.

Main Methods:

• Review of pharmacogenetics research and its implications for drug response.
• Analysis of the role of plasma membrane proteins (RTKs and GPCRs) in drug efficacy and safety.
• Discussion of the impact of genetic variability on drug treatment outcomes.

Main Results:

• Drug response (efficacy and safety) is significantly influenced by interindividual genetic variability.
• Pharmacogenomic insights can guide personalized therapy, moving beyond the "one dose fits all" model.
• Genetic variations in transmembrane protein receptors are key to understanding differential drug responses.

Conclusions:

• Pharmacogenomics is essential for advancing precision medicine and tailoring treatments to individual genetic profiles.
• Understanding genetic variations in receptors like GPCRs is critical for optimizing drug therapies and reducing adverse drug reactions.
• Global harmonization of pharmacogenomic guidelines is needed to facilitate widespread clinical application.